| Literature DB >> 27608431 |
Ana B Benito1, Miren K Aiertza1, Marco Marradi1, Larraitz Gil-Iceta2, Talia Shekhter Zahavi3, Boguslaw Szczupak2, María Jiménez-González2, Torsten Reese2, Eugenio Scanziani4,5, Lorena Passoni4, Michela Matteoli4, Marcella De Maglie4,5, Arie Orenstein6, Mor Oron-Herman6, Gennady Kostenich6, Ludmila Buzhansky3, Ehud Gazit3, Hans-Jurgen Grande1, Vanessa Gómez-Vallejo2, Jordi Llop2, Iraida Loinaz1.
Abstract
The development of tools for the early diagnosis of pancreatic adenocarcinoma is an urgent need in order to increase treatment success rate and reduce patient mortality. Here, we present a modular nanosystem platform integrating soft nanoparticles with a targeting peptide and an active imaging agent for diagnostics. Biocompatible single-chain polymer nanoparticles (SCPNs) based on poly(methacrylic acid) were prepared and functionalized with the somatostatin analogue PTR86 as the targeting moiety, since somatostatin receptors are overexpressed in pancreatic cancer. The gamma emitter 67Ga was incorporated by chelation and allowed in vivo investigation of the pharmacokinetic properties of the nanoparticles using single photon emission computerized tomography (SPECT). The resulting engineered nanosystem was tested in a xenograph mouse model of human pancreatic adenocarcinoma. Imaging results demonstrate that accumulation of targeted SCPNs in the tumor is higher than that observed for nontargeted nanoparticles due to improved retention in this tissue.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27608431 DOI: 10.1021/acs.biomac.6b00941
Source DB: PubMed Journal: Biomacromolecules ISSN: 1525-7797 Impact factor: 6.988